# US 2026/0091104 A1 · Nucleic acid vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091104 A1
- Document ID: US20260091104A1
- Status: Published application
- Kind: A1
- Application number: 19/188,713
- Filed: 2025-04-24
- Published: 2026-04-02
- Earliest claimed: 2014-04-23
- Assignees: ModernaTX, Inc.
- Applicants: ModernaTX, INC.
- Inventors: Giuseppe CIARAMELLA; Axel BOUCHON; Eric YI-CHUN HUANG
- Web page: https://patentgrep.com/patent/US20260091104A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 39/12: Viral antigens
- A61K 39/155: Paramyxoviridae, e.g. parainfluenza virus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 31/16: for influenza or rhinoviruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.

## Claims

### Claim 1

A vaccine comprising a messenger ribonucleic acid (mRNA) formulated in a lipid nanoparticle, wherein the mRNA in the vaccine comprises an open reading frame encoding an influenza hemagglutinin protein, wherein the open reading frame comprises nucleosides consisting of N1-methylpseudouridine, adenosine, guanosine, and cytidine, and wherein the lipid nanoparticle comprises an ionizable cationic lipid, a neutral lipid, a sterol, and a PEG-modified lipid.

### Claim 2 (depends on 1)

The vaccine of claim 1, wherein the influenza hemagglutinin protein is an influenza A H1 hemagglutinin protein.

### Claim 3 (depends on 1)

The vaccine of claim 1, wherein the influenza hemagglutinin protein is an influenza A H3 hemagglutinin protein.

### Claim 4 (depends on 3)

The vaccine of claim 3, wherein the vaccine further comprises an mRNA comprising an open reading frame encoding an influenza A H1 hemagglutinin protein formulated in the lipid nanoparticle, wherein the open reading frame encoding the influenza A H1 hemagglutinin protein comprises nucleosides consisting of N1-methylpseudouridine, adenosine, guanosine, and cytidine.

### Claim 5 (depends on 3)

The vaccine of claim 3, wherein the vaccine further comprises an mRNA comprising an open reading frame encoding an influenza A H1 hemagglutinin protein formulated in a second lipid nanoparticle, wherein the second lipid nanoparticle comprises an ionizable cationic lipid, a neutral lipid, a sterol, and a PEG-modified lipid, and wherein the open reading frame encoding the influenza A H1 hemagglutinin protein comprises nucleosides consisting of N1-methylpseudouridine, adenosine, guanosine, and cytidine.

### Claim 6 (depends on 4)

The vaccine of claim 4, wherein the vaccine comprises from 25-100 μg mRNA.

### Claim 7 (depends on 5)

The vaccine of claim 5, wherein the vaccine comprises from 25-100 μg mRNA.

### Claim 8 (depends on 6)

The vaccine of claim 6, wherein the lipid nanoparticle comprises 20-60 mol % of the ionizable cationic lipid, 5-25 mol % of the neutral lipid, 25-55 mol % of the sterol, and 0.5-15 mol % of the PEG-modified lipid.

### Claim 9 (depends on 7)

The vaccine of claim 7, wherein the lipid nanoparticle comprises 20-60 mol % of the ionizable cationic lipid, 5-25 mol % of the neutral lipid, 25-55 mol % of the sterol, and 0.5-15 mol % of the PEG-modified lipid.

### Claim 10

The vaccine of 8, wherein the neutral lipid is DSPC and the sterol is a cholesterol.

### Claim 11

The vaccine of 9, wherein the neutral lipid is DSPC and the sterol is a cholesterol.

### Claim 12

A method of vaccinating a human subject against influenza, the method comprising administering to the human subject a dose of a vaccine comprising a messenger ribonucleic acid (mRNA) formulated in a lipid nanoparticle, wherein the mRNA comprises an open reading frame encoding an influenza hemagglutinin protein, wherein the open reading frame comprises nucleosides consisting of N1-methyl-pseudouridine, adenosine, guanosine, and cytidine, wherein the lipid nanoparticle comprises an ionizable cationic lipid, a neutral lipid, a cholesterol, and a polyethylene glycol (PEG)-modified lipid, and wherein the vaccine is administered intramuscularly.

### Claim 13 (depends on 12)

The method of claim 12, wherein the influenza hemagglutinin protein is an influenza A H1 hemagglutinin protein.

### Claim 14 (depends on 12)

The method of claim 12, wherein the influenza hemagglutinin protein is an influenza A H3 hemagglutinin protein.

### Claim 15 (depends on 14)

The method of claim 14, wherein the vaccine further comprises an mRNA comprising an open reading frame encoding an influenza A H1 hemagglutinin protein formulated in the lipid nanoparticle, wherein the open reading frame encoding the influenza A H1 hemagglutinin protein comprises nucleosides consisting of N1-methylpseudouridine, adenosine, guanosine, and cytidine.

### Claim 16 (depends on 14)

The method of claim 14, wherein the vaccine further comprises an mRNA comprising an open reading frame encoding an influenza A H1 hemagglutinin protein formulated in a second lipid nanoparticle, wherein the second lipid nanoparticle comprises an ionizable cationic lipid, a neutral lipid, a sterol, and a PEG-modified lipid, and wherein the open reading frame encoding the influenza A H1 hemagglutinin protein comprises nucleosides consisting of N1-methylpseudouridine, adenosine, guanosine, and cytidine.

### Claim 17 (depends on 15)

The method of claim 15, wherein the vaccine comprises from 25-100 μg mRNA.

### Claim 18 (depends on 16)

The method of claim 16, wherein the vaccine comprises from 25-100 μg mRNA.

### Claim 19 (depends on 17)

The method of claim 17, wherein the lipid nanoparticle comprises 20-60 mol % ionizable cationic lipid, 5-25 mol % DSPC, 25-55 mol % cholesterol, and 0.5-15 mol % PEG-modified lipid.

### Claim 20 (depends on 19)

The method of claim 19, wherein the lipid nanoparticle comprises 20-60 mol % ionizable cationic lipid, 5-25 mol % DSPC, 25-55 mol % cholesterol, and 0.5-15 mol % PEG-modified lipid.
